前列腺癌盆腔放疗对整体代谢谱及微生物驱动的胃肠道晚期副作用的影响:一项纵向观察研究
该纵向观察研究对32例接受前列腺及盆腔淋巴结放疗的高危前列腺癌患者,在基线、放疗中2–3周和4–5周及放疗后3、6、12个月共6个时间点采集尿液、血浆和粪便,用核磁共振和超高效液相色谱-质谱分析代谢谱。结果显示放疗启动后尿液、血浆和粪便代谢物显著改变,且至放疗后1年未恢复基线;血浆中心血管风险相关分子升高,放疗前粪便丁酸盐水平及放疗期间至放疗后1年下降幅度与胃肠道副作用增加相关。
要点
- 盆腔放疗后尿液、血浆和粪便代谢谱显著改变,且1年内未恢复基线。
- 血浆中心血管风险相关分子在放疗后升高。
- 放疗前粪便丁酸盐水平及放疗期间下降幅度与胃肠道副作用增加相关。
核心结论
- 首次显示接受前列腺及盆腔淋巴结放疗的患者在放疗后1年内存在整体代谢效应,这些代谢改变可能影响长期发病率,值得进一步研究。
研究设计与样本
- 纵向观察研究,纳入32例接受前列腺及盆腔淋巴结放疗的高危前列腺癌患者。
- 在基线、放疗中2–3周和4–5周及放疗后3、6、12个月共6个时间点采集尿液、血浆和粪便样本。
- 用1H核磁共振波谱和超高效液相色谱-质谱分析尿液和血浆代谢组,用核磁共振分析粪便。
- 采用线性混合效应模型分析各生物流体和检测方法在不同时间点间的代谢变化并确定感兴趣代谢物。
主要发现
- 放疗启动后尿液、血浆和粪便中的代谢物显著改变。
- 任何生物流体中的代谢谱在放疗后1年内均未恢复至基线。
- 血浆中心血管风险相关分子升高。
- 放疗前粪便丁酸盐水平与胃肠道副作用增加直接相关,放疗期间至放疗后1年丁酸盐更大幅下降亦与胃肠道副作用增加相关,与既往宏分类学结果一致。
临床怎么用
- 对接受前列腺及盆腔淋巴结放疗的高危前列腺癌患者,可关注放疗前粪便丁酸盐水平及放疗期间至放疗后1年的下降幅度,以识别胃肠道晚期副作用风险较高的患者。
- 放疗后1年内应关注代谢谱改变及血浆心血管风险相关分子的升高,并将其纳入长期随访评估。
局限性
- 样本量32例,为单中心纵向观察研究,结果需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Radiation therapy to the prostate and pelvic lymph nodes (PLNRT) is part of the curative treatment of high-risk prostate cancer. Yet, the broader influence of radiation therapy on patient physiology is poorly understood. We conducted comprehensive global metabolomic profiling of urine, plasma, and stools sampled from patients undergoing PLNRT for high-risk prostate cancer. METHODS AND MATERIALS: Samples were taken from 32 patients at 6 timepoints: baseline, 2 to 3 and 4 to 5 weeks of PLNRT; and 3, 6, and 12 months after PLNRT. We characterized the global metabolome of urine and plasma using 1H nuclear magnetic resonance spectroscopy and ultraperformance liquid chromatography-mass spectrometry, and of stools with nuclear magnetic resonance. Linear mixed-effects modeling was used to investigate metabolic changes between timepoints for each biofluid and assay and determine metabolites of interest. RESULTS: Metabolites in urine, plasma and stools changed significantly after PLNRT initiation. Metabolic profiles did not return to baseline up to 1 year post-PLNRT in any biofluid. Molecules associated with cardiovascular risk were increased in plasma. Pre-PLNRT fecal butyrate levels directly associated with increasing gastrointestinal side effects, as did a sharper fall in those levels during and up to 1 year postradiation therapy, mirroring our previous results with metataxonomics. CONCLUSIONS: We showed for the first time that an overall metabolic effect is observed in patients undergoing PLNRT up to 1 year posttreatment. These metabolic changes may effect on long-term morbidity after treatment, which warrants further investigation.
引用
- Ferreira MR, Sands CJ, Li JV, et al. Impact of Pelvic Radiation Therapy for Prostate Cancer on Global Metabolic Profiles and Microbiota-Driven Gastrointestinal Late Side Effects: A Longitudinal Observational Study. Int J Radiat Oncol Biol Phys. 2021. PMID: 34352290. doi:10.1016/j.ijrobp.2021.07.1713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。